FINHUB Insights

AMGN · Q1 FY25 · Jan 1 – Mar 31, 2025

Amgen Q1 FY25: where the revenue came from and where it went

Amgen Q1 FY25: revenue $8.1B (+9% year over year). Net profit $1.7B. Largest cohort Other $2.8B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 1 – Mar 31, 2025
Reported
May 2, 2025 10-Q
Sankey diagram of Amgen's income statement for Q1 FY25: revenue of $8.1 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$8.1B +9% year over year
Gross profit$5.2B 64% margin
Operating profit$1.2B 14% margin
Net profit$1.7B 21% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
ItemValueShare of revenueYear over year
Revenue 8.1 100% +9%
Other 2.8 35%
Other Products 1.6 20% +20%
Prolia 1.1 14% +10%
Repathaevolocumab 0.7 9% +27%
Xgeva 0.6 7% +1%
Enbrel 0.5 6% −10%
EVENITY 0.4 5% +29%
Otezla 0.4 5% +11%
Cost of revenue−337%
Gross profit5.264% margin+7pp
SG&A−1.721%−4pp
Other−2.328%+0pp
Operating profit1.214% margin+1pp
Tax−0.3
Net profit1.721%+23pp
Filing on EDGAR More quarters of AMGN

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters